Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 16/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 16/20 | 1.00 |
| ▸ | NPC1 | O15118 | 7/20 | 1.00 |
| ▸ | HPN | P05981 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 6/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | AR | P10275 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | PBRM1 | Q86U86 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | IDE | P14735 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13035685 | 0.82 | MEN1 (1.00) | MEN1KMT2ANPC1HPNGAA | |
| SCHEMBL13035699 | 0.80 | MEN1 (1.00) | MEN1KMT2ANPC1HPNGAA | |
| SCHEMBL14709209 | 0.79 | MEN1 (1.00) | MEN1KMT2ANPC1HPNGAA | |
| SCHEMBL14709208 | 0.79 | MEN1 (0.70) | MEN1KMT2ANPC1HPNGAA | |
| SCHEMBL13035693 | 0.79 | MEN1 (1.00) | MEN1KMT2ANPC1HPNGAA | |
| SCHEMBL13035675 | 0.79 | MEN1 (0.84) | MEN1KMT2ANPC1HPNGAA | |
| SCHEMBL16229294 | 0.77 | MEN1 (0.68) | MEN1KMT2ANPC1HPNGAA | |
| SCHEMBL12403784 | 0.77 | MEN1 (0.63) | MEN1KMT2ANPC1HPNGAA | |
| SCHEMBL30256834 | 0.76 | TNKS2 (0.69) | MEN1KMT2ANPC1HPNGAA | |
| SCHEMBL28902364 | 0.76 | TNKS2 (0.69) | MEN1KMT2ANPC1HPNGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9182402-B2 | Hepsin inhibitors | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2015-11-10 | — | — | US | claimed |
| US-20140127127-A1 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2014-05-08 | — | — | US | claimed |
| US-8450334-B2 | Hepsin inhibitors | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2013-05-28 | — | — | US | claimed |
| US-20110144139-A1 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER | 2011-06-16 | — | — | US | claimed |
| US-9182402-B2 | Hepsin inhibitors | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2015-11-10 | — | — | US | disclosed |
| US-9182402-B2 | Hepsin inhibitors | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2015-11-10 | — | — | US | disclosed |
| US-9182402-B2 | Hepsin inhibitors | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140127127-A1 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140127127-A1 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140127127-A1 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2014-05-08 | — | — | US | disclosed |
| US-8664266-B2 | Hepsin inhibitors | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664266-B2 | Hepsin inhibitors | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2014-03-04 | — | — | US | disclosed |
| US-20110144139-A1 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER | 2011-06-16 | — | — | US | disclosed |
| US-20110144139-A1 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER | 2011-06-16 | — | — | US | disclosed |
| US-20110144139-A1 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER | 2011-06-16 | — | — | US | disclosed |
| US-20100297046-A1 | Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors | DYNAMIS THERAPEUTICS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100297046-A1 | Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors | DYNAMIS THERAPEUTICS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2009151920-A2 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009151920-A2 | HEPSIN INHIBITORS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2007117394-A2 | COMPOSITIONS AND METHODS RELATED TO FRUCTOSAMINE-3-KINASE INHIBITORS | DYNAMIS THERAPEUTICS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297046-A1 | Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors | FN3K, ROS1, FN3KRP | MEN1 4765/4885KMT2A 2677/4885NPC1 3021/4885 |
| US-20140127127-A1 | HEPSIN INHIBITORS | HPN, TMPRSS2, SPINT2 | MEN1 286/4885KMT2A 2624/4885NPC1 673/4885 |
| US-20110144139-A1 | HEPSIN INHIBITORS | HPN, TMPRSS2, SPINT2 | MEN1 286/4885KMT2A 2624/4885NPC1 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.